Background: Cardiac implantable electronic device (CIED) infection is a serious adverse event, but there are limited contemporary real-world data on treatment pathways and associated costs in the Medicare population following diagnosis of CIED infection. Hence, this study evaluates postinfection treatment pathways and associated healthcare expenditures and mortality among Medicare fee-for-service beneficiaries with CIED infection.
INTRODUCTION
Infection remains a serious complication following cardiac implantable electronic device (CIED) implantation. [1] [2] [3] The threefold rise in CIED infection rate has surpassed the growth rate of CIED implantation over the past 20 years. [4] [5] [6] [7] [8] wileyonlinelibrary.com/journal/paceutilization including hospital, emergency room (ER), and postacute care settings among Medicare fee-for-service (FFS) beneficiaries with CIED infection.
METHODS
We performed a retrospective cohort analysis of Medicare FFS beneficiaries who received an initial implantation or replacement (includ- 
RESULTS

Patient characteristics
A total of 5,401 Medicare beneficiaries (mean age 77.4 years; 62.9% male) had evidence of CIED infection in the 12-month period following initial implantation or replacement of a CIED. Baseline characteristics, overall and by infection treatment group, are reported in Table 1 . 
Timing from infection to device extraction
Of those with device extraction (Groups IA and IB), the time from first (Table 2 ).
Healthcare resource utilization and Medicare expenditures
There was substantial healthcare resource utilization for the entire infection cohort. This included both utilization related and unrelated to the infection. In the 12-month period following infection, 43% of the entire group of patients had at least one ER visit (not resulting in hospital admission) and 62% were hospitalized ( CCI = Charlson Comorbidity Index; CHF = congestive heart failure; CIED = cardiac implantable electronic device; CKD = chronic kidney disease; CRT-D = cardiac resynchronization therapy device with defibrillator; CRT-P = cardiac resynchronization therapy device without defibrillator; SD = standard deviation.
Medicare payments were highest among patients who did not receive a device revision or replacement following infection but experienced at least one infection-related hospitalization (Group IIA). Hospitalizations were the largest cost driver (Figure 3 ). Infection-related payments as percentage of total payments varied from 52% to 65% among patients who required surgical intervention or hospitalization (Groups IA, IB, IIA) ( Figure 3) . Overall, across all treatment groups, infectionrelated payments accounted for more than half of all payments in the year following CIED infection.
Mortality
A total of 25.3% of patients (n = 1,369) died during the follow-up period Note: *Procedure date were not reported in some cases. Results shown for patients with valid procedure date. Visibility into diagnosis of infection and extraction based on facility-based medical claims; claims for physician office visits were not available for analysis. Abbreviations as in Table 1 .
F I G U R E 2
All-cause and infection-related ER visits and hospitalizations during follow-up period, by intervention group. Legend: IA: Generator/system removed and replaced; IB: Generator/system removed but not replaced; IIA: No device procedure but 1+ infection-specific hospitalization; IIB: No device procedure and no infection-specific hospitalization. ER = emergency room [Color figure can be viewed at wileyonlinelibrary.com] intervention were associated with poorer survival (Table 4) In sensitivity analyses, we evaluated differences in all-cause Medi- 
DISCUSSION
The present study analyzed the treatment patterns and costs associ- 
) -
Note: *ALOS = average length of stay (in days).
In our analysis, the majority of Medicare beneficiaries with CIED infection were managed with device extraction, consistent with current guidelines for the management of CIED infection. 7 Of these, 56% (n = 1,949) were hospitalized for the extraction, while 44%
(n = 1,515) were managed in the outpatient setting. Group IIA (infection-related hospitalization but no CIED intervention) had the highest rate of comorbidities and mortality, suggesting that these patients were not healthy enough to undergo device extraction proce- Abbreviations as in Table 1 . 
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